Condensed Consolidated Balance Sheets - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Current Assets:
Cash and cash equivalents	$ 2,373,936	$ 675,705
Accounts receivable, net	1,378,894	1,337,545
Other receivables, current portion	586,734	393,821
Prepaid expenses and other current assets	163,323	161,838
Total current assets	4,502,887	2,568,909
Property and equipment, net	427,195	400,321
Intangible assets	22,358,567
Other receivables, net of current portion	87,354	57,352
Acquisition deposits	1,104,985	1,112,404
Goodwill	600,084	604,113
TOTAL ASSETS	29,081,072	4,743,099
Current Liabilities:
Accounts payable	1,254,234	1,307,599
Accrued expenses	254,667	383,998
Accrued interest (principally to related parties)	181,740	156,121
Due to related parties	966,102	1,116,261
Notes payable, current portion	379,800	382,350
Total current liabilities	3,036,543	3,346,329
Debentures, related parties	1,215,837	1,224,000
TOTAL LIABILITIES	4,252,380	4,570,329
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2019 and August 31, 2018
Common stock; $0.001par value; 499,000,000 shares authorized; 223,048,205 and 207,881,743 shares issued and outstanding at February 28, 2019 and August 31, 2018	223,048	207,882
Additional paid-in capital	35,047,853	10,053,683
Other comprehensive income	1,165,795	1,139,815
Accumulated deficit	(11,570,906)	(11,199,989)
Total Novo Integrated Sciences, Inc. stockholders' equity	24,865,790	201,391
Noncontrolling interest	(37,098)	(28,621)
Total stockholders' equity	24,828,692	172,770
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 29,081,072	$ 4,743,099